s6y

GSK plc

NYSE
GSK
OTC
GLAXF
CIK
1131399
Industry
Pharmaceutical Preparations
Incorporated in
United Kingdom
SEC filer category
Large accelerated filer
Formerly
Glaxosmithkline plc

Key figures

Fiscal year to Dec 2025 Dec 2024 Dec 2023 Dec 2022 Dec 2021
Revenue £32.7B£31.4B£30.3B£29.3B£24.7B
Operating income £7.93B£4.02B£6.75B£6.43B£4.36B
Net income £5.72B£2.58B£4.93B£15.0B£4.38B
Diluted EPS £1.39£0.62£1.20£3.66£1.08
Cash from operations £7.74B£6.55B£6.77B£7.40B£7.95B
Total assets £61.1B£59.5B£59.0B£60.1B£79.1B
Shareholders’ equity £16.4B£13.7B£13.3B£10.6B£15.1B

From the company’s annual reports to the SEC, in GBP. Each year links to its report.

Financials 27

  1. 20-F Annual report (foreign issuer) for period ending Dec 31, 2025
  2. 20-F Annual report (foreign issuer) for period ending Dec 31, 2024
  3. 20-F Annual report (foreign issuer) for period ending Dec 31, 2023
  4. 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2022
  5. 20-F Annual report (foreign issuer) for period ending Dec 31, 2022
  6. 20-F Annual report (foreign issuer) for period ending Dec 31, 2021
  7. 20-F Annual report (foreign issuer) for period ending Dec 31, 2020
  8. 20-F Annual report (foreign issuer) for period ending Dec 31, 2019
  9. 20-F Annual report (foreign issuer) for period ending Dec 31, 2018
  10. 20-F/A Annual report (foreign issuer) for period ending Dec 31, 2017

All 27 financials filings

News 6,185

  1. 6-K Transfer of Treasury Shares
  2. 6-K Velzatinib Obtains Odd in Japan for Gist Treatment
  3. 6-K Fda Approves Nelkarmi for Pretreated Alk+ NSCLC
  4. 6-K Director/PDMR Shareholding
  5. 6-K Bexsero Booster Receives Positive CHMP Opinion
  6. 6-K Director/PDMR Shareholding
  7. 6-K GSK Publishes Provisional Dividend Dates
  8. 6-K Total Voting Rights
  9. 6-K 3RD Quarter Results
  10. 6-K Ris-Rez Positive PH 3 Osteosarcoma Data in China

All 6,185 news filings

Ownership 342

  1. 144 Martinez Maria E (Officer): plans to sell 44,397 shares ($2.3M)
  2. SCHEDULE 13G/A Dodge & Cox: holds 4.3%
  3. SCHEDULE 13G FMR LLC: holds 5.8%
  4. 4 Change in insider ownership
  5. SCHEDULE 13D/A Major shareholder report
  6. SCHEDULE 13D Major shareholder report
  7. SCHEDULE 13D/A Major shareholder report
  8. SCHEDULE 13G/A Major shareholder report (passive investor)
  9. SC 13D/A Major shareholder report
  10. SC 13G/A Major shareholder report (passive investor)

All 342 ownership filings

Prospectus 98

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  3. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  4. 424B2 Prospectus filed pursuant to Rule 424(b)(2)
  5. SC TO-T/A Third party tender offer statement
  6. SC TO-T/A Third party tender offer statement
  7. SC TO-T/A Third party tender offer statement
  8. SC TO-T/A Third party tender offer statement
  9. SC TO-T Third party tender offer statement
  10. SC TO-C Written communication relating to an issuer or third party tender offer

All 98 prospectus filings

Proxies 1

  1. DFAN14A Sierra Oncology, Inc.: Definitive additional proxy soliciting materials filed by non-management including Rule 14(a)(12) material

Other 207

  1. 13F-HR 13 holdings worth $497M
  2. CERT Certification by an exchange approving securities for listing
  3. 8-A12B Form for the registration / listing of a class of securities on a national securities exchange pursuant to Section 12(b)
  4. 13F-HR Institutional holdings report
  5. 11-K Annual report of employee stock purchase, savings and similar plans
  6. 11-K Annual report of employee stock purchase, savings and similar plans
  7. SD Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
  8. 13F-HR Institutional holdings report
  9. IRANNOTICE Notice of disclosure filed in Exchange Act quarterly and annual reports pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act
  10. 13F-HR Institutional holdings report

All 207 other filings

Others in Pharmaceutical Preparations

Every company in this industry